Global Antibody Drug Conjugate Linker And Conjugation Technologies Industry

Global Antibody Drug Conjugate Linker And Conjugation Technologies Industry Research & Trends Analysis Report

Global Antibody Drug Conjugate Linker And Conjugation Technologies Industry

Global Antibody Drug Conjugate Linker And Conjugation Technologies Industry Research & Trends Analysis Report


The research report on ‘Antibody Drug Conjugate Linker And Conjugation Technologies Market’ provides a workplan for stakeholders for the estimated timeframe of 2024-. To elaborate, it offers valid predictions for the size, shares, and growth patterns of this domain over the projected timeline by assessing the past records and present business trends.

Exclusive deal : 20% Instant discount on Direct purchases! Don't wait—claim your discount today!

According to A Latest intelligence report published by Market IntelliX, the global market for Antibody Drug Conjugate Linker And Conjugation Technologies should grow from US$ million in 2022 to US$ million by 2029, with a CAGR of % for the period of 2023-2029.

China Antibody Drug Conjugate Linker And Conjugation Technologies market should grow from US$ million in 2022 to US$ million by 2029, with a CAGR of % for the period of 2023-2029.

The United States Antibody Drug Conjugate Linker And Conjugation Technologies market should grow from US$ million in 2022 to US$ million by 2029, with a CAGR of % for the period of 2023-2029.

In terms of type, Chemical Conjugation segment holds a share about % in 2022 and will reach % in 2029; while in terms of application, Leukemia has a share approximately % in 2022 and will grow at a CAGR % during 2023 and 2029.

The global key manufacturers of Antibody Drug Conjugate Linker And Conjugation Technologies include Seattle Genetics Inc, Immunogen, Ambrx, Catalent Biologics, Immunomedics, Mersana Therapeutics, Sutro Biopharma, Iksuda Therapeutics and Legochem Biosciences, etc. In 2022, the global top five players hold a share approximately % in terms of revenue.

This report aims to provide a comprehensive study of the global market for Antibody Drug Conjugate Linker And Conjugation Technologies. Report Highlights:

(1) Global Antibody Drug Conjugate Linker And Conjugation Technologies market size (value), history data from 2018-2022 and forecast data from 2023 to 2029.

(2) Global Antibody Drug Conjugate Linker And Conjugation Technologies market competitive situation, revenue and market share, from 2018 to 2022.

(3) China Antibody Drug Conjugate Linker And Conjugation Technologies market competitive situation, revenue and market share, from 2018 to 2022.

(4) Global Antibody Drug Conjugate Linker And Conjugation Technologies segment by region (or country), key regions cover the United States, Europe, Japan, South Korea, Southeast Asia and India, etc.

(5) Global Antibody Drug Conjugate Linker And Conjugation Technologies segment by type and by application and regional segment by type and by application.

(6) Antibody Drug Conjugate Linker And Conjugation Technologies industry supply chain, upstream, midstream and downstream analysis.

Market segment by regions, regional analysis covers

North America (United States, Canada and Mexico)

Europe (Germany, France, UK, Russia, Italy and Rest of Europe)

Asia-Pacific (China, Japan, South Korea, India, Southeast Asia, Australia and Rest of Asia-Pacific)

South America (Brazil, Rest of South America)

Middle East & Africa

Market segment by type, covers

Chemical Conjugation

Enzymatic Conjugation

Market segment by application, can be divided into

Leukemia

Lymphoma

Breast Cancer

Others

Market segment by players, this report covers

Seattle Genetics Inc

Immunogen

Ambrx

Catalent Biologics

Immunomedics

Mersana Therapeutics

Sutro Biopharma

Iksuda Therapeutics

Legochem Biosciences

Linxis

Adc Therapeutics

1 Market Overview

1.1 Product Overview and Scope of Antibody Drug Conjugate Linker And Conjugation Technologies

1.2 Global Antibody Drug Conjugate Linker And Conjugation Technologies Market Size and Forecast

1.3 China Antibody Drug Conjugate Linker And Conjugation Technologies Market Size and Forecast

1.4 China Market Percentage in Global

1.4.1 By Revenue, China Antibody Drug Conjugate Linker And Conjugation Technologies Share in Global Market, 2018-2029

1.4.2 Antibody Drug Conjugate Linker And Conjugation Technologies Market Size: China VS Global, 2018-2029

1.5 Antibody Drug Conjugate Linker And Conjugation Technologies Market Dynamics

1.5.1 Antibody Drug Conjugate Linker And Conjugation Technologies Market Drivers

1.5.2 Antibody Drug Conjugate Linker And Conjugation Technologies Market Restraints

1.5.3 Antibody Drug Conjugate Linker And Conjugation Technologies Industry Trends

1.5.4 Antibody Drug Conjugate Linker And Conjugation Technologies Industry Policy

2 Global Competitive Situation by Company

2.1 Global Antibody Drug Conjugate Linker And Conjugation Technologies Revenue by Company (2018-2023)

2.2 Global Antibody Drug Conjugate Linker And Conjugation Technologies Participants, Market Position (Tier 1, Tier 2 and Tier 3)

2.3 Global Antibody Drug Conjugate Linker And Conjugation Technologies Concentration Ratio

2.4 Global Antibody Drug Conjugate Linker And Conjugation Technologies Mergers & Acquisitions, Expansion Plans

2.5 Global Antibody Drug Conjugate Linker And Conjugation Technologies Manufacturers Product Type

3 China Competitive Situation by Company

3.1 China Antibody Drug Conjugate Linker And Conjugation Technologies Revenue by Company (2018-2023)

3.2 China Antibody Drug Conjugate Linker And Conjugation Technologies Antibody Drug Conjugate Linker And Conjugation Technologies Participants, Market Position (Tier 1, Tier 2 and Tier 3)

3.3 China Antibody Drug Conjugate Linker And Conjugation Technologies, Revenue Percentage of Local Players VS Foreign Manufacturers (2018-2023)

4 Industry Chain Analysis

4.1 Antibody Drug Conjugate Linker And Conjugation Technologies Industry Chain

4.2 Antibody Drug Conjugate Linker And Conjugation Technologies Upstream Analysis

4.3 Antibody Drug Conjugate Linker And Conjugation Technologies Midstream Analysis

4.4 Antibody Drug Conjugate Linker And Conjugation Technologies Downstream Analysis

5 Sights by Type

5.1 Antibody Drug Conjugate Linker And Conjugation Technologies Classification

5.1.1 Chemical Conjugation

5.1.2 Enzymatic Conjugation

5.2 By Type, Global Antibody Drug Conjugate Linker And Conjugation Technologies Market Size & CAGR, 2018 VS 2022 VS 2029

5.3 By Type, Global Antibody Drug Conjugate Linker And Conjugation Technologies Revenue, 2018-2029

6 Sights by Application

6.1 Antibody Drug Conjugate Linker And Conjugation Technologies Segment by Application

6.1.1 Leukemia

6.1.2 Lymphoma

6.1.3 Breast Cancer

6.1.4 Others

6.2 By Application, Global Antibody Drug Conjugate Linker And Conjugation Technologies Market Size & CAGR, 2018 VS 2022 VS 2029

6.3 By Application, Global Antibody Drug Conjugate Linker And Conjugation Technologies Revenue, 2018-2029

7 Sales Sights by Region

7.1 By Region, Global Antibody Drug Conjugate Linker And Conjugation Technologies Market Size, 2018 VS 2022 VS 2029

7.2 By Region, Global Antibody Drug Conjugate Linker And Conjugation Technologies Market Size, 2018-2029

7.3 North America

7.3.1 North America Antibody Drug Conjugate Linker And Conjugation Technologies Market Size & Forecasts, 2018-2029

7.3.2 By Country, North America Antibody Drug Conjugate Linker And Conjugation Technologies Market Size Market Share

7.4 Europe

7.4.1 Europe Antibody Drug Conjugate Linker And Conjugation Technologies Market Size & Forecasts, 2018-2029

7.4.2 By Country, Europe Antibody Drug Conjugate Linker And Conjugation Technologies Market Size Market Share

7.5 Asia Pacific

7.5.1 Asia Pacific Antibody Drug Conjugate Linker And Conjugation Technologies Market Size & Forecasts, 2018-2029

7.5.2 By Country/Region, Asia Pacific Antibody Drug Conjugate Linker And Conjugation Technologies Market Size Market Share

7.6 South America

7.6.1 South America Antibody Drug Conjugate Linker And Conjugation Technologies Market Size & Forecasts, 2018-2029

7.6.2 By Country, South America Antibody Drug Conjugate Linker And Conjugation Technologies Market Size Market Share

7.7 Middle East & Africa

8 Sights by Country Level

8.1 By Country, Global Antibody Drug Conjugate Linker And Conjugation Technologies Market Size & CAGR，2018 VS 2022 VS 2029

8.2 By Country, Global Antibody Drug Conjugate Linker And Conjugation Technologies Market Size, 2018-2029

8.3 U.S.

8.3.1 U.S. Antibody Drug Conjugate Linker And Conjugation Technologies Market Size, 2018-2029

8.3.2 By Company, U.S. Antibody Drug Conjugate Linker And Conjugation Technologies Revenue Market Share, 2018-2023

8.3.3 By Type, U.S. Antibody Drug Conjugate Linker And Conjugation Technologies Revenue Market Share, 2022 VS 2029

8.3.4 By Application, U.S. Antibody Drug Conjugate Linker And Conjugation Technologies Revenue Market Share, 2022 VS 2029

8.4 Europe

8.4.1 Europe Antibody Drug Conjugate Linker And Conjugation Technologies Market Size, 2018-2029

8.4.2 By Company, Europe Antibody Drug Conjugate Linker And Conjugation Technologies Revenue Market Share, 2018-2023

8.4.3 By Type, Europe Antibody Drug Conjugate Linker And Conjugation Technologies Revenue Market Share, 2022 VS 2029

8.4.4 By Application, Europe Antibody Drug Conjugate Linker And Conjugation Technologies Revenue Market Share, 2022 VS 2029

8.5 China

8.5.1 China Antibody Drug Conjugate Linker And Conjugation Technologies Market Size, 2018-2029

8.5.2 By Company, China Antibody Drug Conjugate Linker And Conjugation Technologies Revenue Market Share, 2018-2023

8.5.3 By Type, China Antibody Drug Conjugate Linker And Conjugation Technologies Revenue Market Share, 2022 VS 2029

8.5.4 By Application, China Antibody Drug Conjugate Linker And Conjugation Technologies Revenue Market Share, 2022 VS 2029

8.6 Japan

8.6.1 Japan Antibody Drug Conjugate Linker And Conjugation Technologies Market Size, 2018-2029

8.6.2 By Company, Japan Antibody Drug Conjugate Linker And Conjugation Technologies Revenue Market Share, 2018-2023

8.6.3 By Type, Japan Antibody Drug Conjugate Linker And Conjugation Technologies Revenue Market Share, 2022 VS 2029

8.6.4 By Application, Japan Antibody Drug Conjugate Linker And Conjugation Technologies Revenue Market Share, 2022 VS 2029

8.7 South Korea

8.7.1 South Korea Antibody Drug Conjugate Linker And Conjugation Technologies Market Size, 2018-2029

8.7.2 By Company, South Korea Antibody Drug Conjugate Linker And Conjugation Technologies Revenue Market Share, 2018-2023

8.7.3 By Type, South Korea Antibody Drug Conjugate Linker And Conjugation Technologies Revenue Market Share, 2022 VS 2029

8.7.4 By Application, South Korea Antibody Drug Conjugate Linker And Conjugation Technologies Revenue Market Share, 2022 VS 2029

8.8 Southeast Asia

8.8.1 Southeast Asia Antibody Drug Conjugate Linker And Conjugation Technologies Market Size, 2018-2029

8.8.2 By Company, Southeast Asia Antibody Drug Conjugate Linker And Conjugation Technologies Revenue Market Share, 2018-2023

8.8.3 By Type, Southeast Asia Antibody Drug Conjugate Linker And Conjugation Technologies Revenue Market Share, 2022 VS 2029

8.8.4 By Application, Southeast Asia Antibody Drug Conjugate Linker And Conjugation Technologies Revenue Market Share, 2022 VS 2029

8.9 India

8.9.1 India Antibody Drug Conjugate Linker And Conjugation Technologies Market Size, 2018-2029

8.9.2 By Company, India Antibody Drug Conjugate Linker And Conjugation Technologies Revenue Market Share, 2018-2023

8.9.3 By Type, India Antibody Drug Conjugate Linker And Conjugation Technologies Revenue Market Share, 2022 VS 2029

8.9.4 By Application, India Antibody Drug Conjugate Linker And Conjugation Technologies Revenue Market Share, 2022 VS 2029

8.10 Middle East & Asia

8.10.1 Middle East & Asia Antibody Drug Conjugate Linker And Conjugation Technologies Market Size, 2018-2029

8.10.2 By Company, Middle East & Asia Antibody Drug Conjugate Linker And Conjugation Technologies Revenue Market Share, 2018-2023

8.10.3 By Type, Middle East & Asia Antibody Drug Conjugate Linker And Conjugation Technologies Revenue Market Share, 2022 VS 2029

8.10.4 By Application, Middle East & Asia Antibody Drug Conjugate Linker And Conjugation Technologies Revenue Market Share, 2022 VS 2029

9 Global Manufacturers Profile

9.1 Seattle Genetics Inc

9.1.1 Seattle Genetics Inc Company Information, Head Office, Market Area and Industry Position

9.1.2 Seattle Genetics Inc Company Profile and Main Business

9.1.3 Seattle Genetics Inc Antibody Drug Conjugate Linker And Conjugation Technologies Models, Specifications and Application

9.1.4 Seattle Genetics Inc Antibody Drug Conjugate Linker And Conjugation Technologies Revenue and Gross Margin, 2018-2023

9.1.5 Seattle Genetics Inc Recent Developments

9.2 Immunogen

9.2.1 Immunogen Company Information, Head Office, Market Area and Industry Position

9.2.2 Immunogen Company Profile and Main Business

9.2.3 Immunogen Antibody Drug Conjugate Linker And Conjugation Technologies Models, Specifications and Application

9.2.4 Immunogen Antibody Drug Conjugate Linker And Conjugation Technologies Revenue and Gross Margin, 2018-2023

9.2.5 Immunogen Recent Developments

9.3 Ambrx

9.3.1 Ambrx Company Information, Head Office, Market Area and Industry Position

9.3.2 Ambrx Company Profile and Main Business

9.3.3 Ambrx Antibody Drug Conjugate Linker And Conjugation Technologies Models, Specifications and Application

9.3.4 Ambrx Antibody Drug Conjugate Linker And Conjugation Technologies Revenue and Gross Margin, 2018-2023

9.3.5 Ambrx Recent Developments

9.4 Catalent Biologics

9.4.1 Catalent Biologics Company Information, Head Office, Market Area and Industry Position

9.4.2 Catalent Biologics Company Profile and Main Business

9.4.3 Catalent Biologics Antibody Drug Conjugate Linker And Conjugation Technologies Models, Specifications and Application

9.4.4 Catalent Biologics Antibody Drug Conjugate Linker And Conjugation Technologies Revenue and Gross Margin, 2018-2023

9.4.5 Catalent Biologics Recent Developments

9.5 Immunomedics

9.5.1 Immunomedics Company Information, Head Office, Market Area and Industry Position

9.5.2 Immunomedics Company Profile and Main Business

9.5.3 Immunomedics Antibody Drug Conjugate Linker And Conjugation Technologies Models, Specifications and Application

9.5.4 Immunomedics Antibody Drug Conjugate Linker And Conjugation Technologies Revenue and Gross Margin, 2018-2023

9.5.5 Immunomedics Recent Developments

9.6 Mersana Therapeutics

9.6.1 Mersana Therapeutics Company Information, Head Office, Market Area and Industry Position

9.6.2 Mersana Therapeutics Company Profile and Main Business

9.6.3 Mersana Therapeutics Antibody Drug Conjugate Linker And Conjugation Technologies Models, Specifications and Application

9.6.4 Mersana Therapeutics Antibody Drug Conjugate Linker And Conjugation Technologies Revenue and Gross Margin, 2018-2023

9.6.5 Mersana Therapeutics Recent Developments

9.7 Sutro Biopharma

9.7.1 Sutro Biopharma Company Information, Head Office, Market Area and Industry Position

9.7.2 Sutro Biopharma Company Profile and Main Business

9.7.3 Sutro Biopharma Antibody Drug Conjugate Linker And Conjugation Technologies Models, Specifications and Application

9.7.4 Sutro Biopharma Antibody Drug Conjugate Linker And Conjugation Technologies Revenue and Gross Margin, 2018-2023

9.7.5 Sutro Biopharma Recent Developments

9.8 Iksuda Therapeutics

9.8.1 Iksuda Therapeutics Company Information, Head Office, Market Area and Industry Position

9.8.2 Iksuda Therapeutics Company Profile and Main Business

9.8.3 Iksuda Therapeutics Antibody Drug Conjugate Linker And Conjugation Technologies Models, Specifications and Application

9.8.4 Iksuda Therapeutics Antibody Drug Conjugate Linker And Conjugation Technologies Revenue and Gross Margin, 2018-2023

9.8.5 Iksuda Therapeutics Recent Developments

9.9 Legochem Biosciences

9.9.1 Legochem Biosciences Company Information, Head Office, Market Area and Industry Position

9.9.2 Legochem Biosciences Company Profile and Main Business

9.9.3 Legochem Biosciences Antibody Drug Conjugate Linker And Conjugation Technologies Models, Specifications and Application

9.9.4 Legochem Biosciences Antibody Drug Conjugate Linker And Conjugation Technologies Revenue and Gross Margin, 2018-2023

9.9.5 Legochem Biosciences Recent Developments

9.10 Linxis

9.10.1 Linxis Company Information, Head Office, Market Area and Industry Position

9.10.2 Linxis Company Profile and Main Business

9.10.3 Linxis Antibody Drug Conjugate Linker And Conjugation Technologies Models, Specifications and Application

9.10.4 Linxis Antibody Drug Conjugate Linker And Conjugation Technologies Revenue and Gross Margin, 2018-2023

9.10.5 Linxis Recent Developments

9.11 Adc Therapeutics

9.11.1 Adc Therapeutics Company Information, Head Office, Market Area and Industry Position

9.11.2 Adc Therapeutics Company Profile and Main Business

9.11.3 Adc Therapeutics Antibody Drug Conjugate Linker And Conjugation Technologies Models, Specifications and Application

9.11.4 Adc Therapeutics Antibody Drug Conjugate Linker And Conjugation Technologies Revenue and Gross Margin, 2018-2023

9.11.5 Adc Therapeutics Recent Developments

10 Conclusion

11 Appendix

11.1 Research Methodology

11.2 Data Source

11.2.1 Secondary Sources

11.2.2 Primary Sources

11.3 Market Estimation Model

11.4 Disclaimer

Tables & Figures:
Show more
Research Methodology:
This research study involved the extensive usage of both primary and secondary data sources. The research process involved the study of various factors affecting the industry, including the government policy, market environment, competitive landscape, historical data, present trends in the market, technological innovation, upcoming technologies and the technical progress in related industry, and market risks, opportunities, market barriers and challenges. The following illustrative figure shows the market research methodology applied in this report.
Antibody Drug Conjugate Linker And Conjugation Technologies Market Size Estimation

To estimate market size and trends, we use a combination of top-down and bottom-up methods. This allows us to evaluate the market from various perspectives—by company, region, product type, and end users.

Our estimates are based on actual sales data, excluding any discounts. Segment breakdowns and market shares are calculated using weighted averages based on usage rates and average prices. Regional insights are determined by how widely a product or service is adopted in each area.

Key companies are identified through secondary sources like industry reports and company filings. We then verify revenue estimates and other key data points through primary research, including interviews with industry experts, company executives, and decision-makers.

We take into account all relevant factors that could influence the market and validate our findings with real-world input. Our final insights combine both qualitative and quantitative data to provide a well-rounded view. Please note, these estimates do not account for unexpected changes such as inflation, economic downturns, or policy shifts.

Data Source

Secondary Sources

This study draws on a wide range of secondary sources, including press releases, annual reports, non-profit organizations, industry associations, government agencies, and customs data. We also referred to reputable databases and directories such as Bloomberg, Wind Info, Hoovers, Factiva, Trading Economics, Statista, and others. Additional references include investor presentations, company filings (e.g., SEC), economic data, and documents from regulatory and industry bodies.

These sources were used to gather technical and market-focused insights, identify key players, analyze market segmentation and classification, and track major trends and developments across industries.

Market Size
  • Segmental value
  • Geographic Penetration
  • Product Adoption Rate for Different market
  • Journals, Websites, and Press Releases
  • Annual Reports and SEC Filings
  • Company Websites and Press Releases
  • Public and Paid Databases
  • Market Intellix Data Repository
Market Position of Top Company
  • Product Financials
  • Geographic value Mix
  • Total Company value
  • Business/Segmental value Mix
Qualitative Analysis
  • Influence Factors
  • Market Potential
  • Market Risks and Opportunities
  • Industry Trends
  • Geographical Features
  • Government Policies
  • Company Websites and Press Releases
  • Public and Paid Databases
  • Annual Reports
  • Industry Associations
  • Market Intellix Data Repository

Primary Sources

As part of our primary research, we interviewed a variety of stakeholders from both the supply and demand sides to gather valuable qualitative and quantitative insights.

On the supply side, we spoke with product manufacturers, competitors, industry experts, research institutions, distributors, traders, and raw material suppliers. On the demand side, we engaged with business leaders, marketing and sales heads, technology and innovation directors, supply chain executives, and end users across key organizations.

These conversations helped us better understand market segmentation, pricing, applications, leading players, supply chains, demand trends, industry outlook, and key market dynamics—including risks, opportunities, barriers, and strategic developments.

Key Data Information from Primary Sources

Primary Sources Parameters Key Data
Market Segments(by Application, by Type)
  • Value by Type
  • Status and Forecast
  • Value by Application
  • Value by Regions, Status and Forecast (2025-2031)
  • Value Market Share by Type
  • Value Growth Rate by Type
  • Value by Application
  • Percentage and Growth Rate by Application
  • Value Growth Rate and Market Share by Regions
  • Market Size Status and Forecast (2025-2031)
Total Market
  • Overall Size, Status and Forecast
  • Market Size Status and Forecast (2025-2031)
Frequently asked questions(FAQ's):
Why is the Antibody Drug Conjugate Linker And Conjugation Technologies Market trending toward high growth trajectories?
A dynamic process in the Antibody Drug Conjugate Linker And Conjugation Technologies Market is initiated by new entrants, including competitors from unrelated industries, in addition to the established players like Seagen, Roche, AstraZeneca, Pfizer, Merck, Daiichi Sankyo, Gilead, Amgen, BioNTech, ImmunoGen, Sutro Biopharma, Mersana Therapeutics, Astellas, AbbVie, ADC Therapeutics, Regeneron, Eli Lilly, Sanofi, Novartis, Genentech.
What is the Antibody Drug Conjugate Linker And Conjugation Technologies Market really preparing for?
Companies in the Antibody Drug Conjugate Linker And Conjugation Technologies Industry will need to adapt swiftly to the behavioral changes that are reshaping consumer decision journeys.
What important business segments are segregated by application types in the latest edition of the Antibody Drug Conjugate Linker And Conjugation Technologies Market?
The key business segments in the Antibody Drug Conjugate Linker And Conjugation Technologies Market are segregated by applications [Oncology, Immunotherapy, Biopharmaceuticals, Research Labs] and types [Cleavable Linkers, Non-Cleavable Linkers, Peptide-Based, Polymer-Based, Chemical Conjugation].
What is the size of the Antibody Drug Conjugate Linker And Conjugation Technologies Industry?
According to the report, the Antibody Drug Conjugate Linker And Conjugation Technologies Industry will grow to USD XXX Million by 2030, with a YY% CAGR.
What is really changing the Antibody Drug Conjugate Linker And Conjugation Technologies Market behavior?
Consumer behavior changes will reshape the entire decision-making process and companies in the Antibody Drug Conjugate Linker And Conjugation Technologies Industry will need to adapt quickly.
How does the Antibody Drug Conjugate Linker And Conjugation Technologies Market study reflects the current scenario?
The Antibody Drug Conjugate Linker And Conjugation Technologies study focuses on shifting market dynamics, geopolitical and regulatory regulations, and key players' strategies to carefully analyze demand at risk across multiple industry categories.